Literature DB >> 2478890

The bcl-2 gene encodes a novel G protein.

S Haldar1, C Beatty, Y Tsujimoto, C M Croce.   

Abstract

Little is known about the biochemical or functional nature of the proteins encoded by the bcl-2 gene, which undergoes chromosomal translocation in approximately 85% of follicular lymphoma, 20% of diffuse large cell lymphoma and 10% of chronic lymphocytic leukaemia of B cells. Translocation of bcl-2 sequences from chromosome 18 to the JH segment of the immunoglobulin gene at chromosome band 14q32 in B cells results in deregulated expression of this gene, causing high steady state levels of bcl-2 messenger RNA2. DNA sequence data indicate that bcl-2 encodes two proteins by virtue of alternative splicing, designated as Bcl-2 alpha and Bcl-2 beta, with relative molecular masses of 26,000 and 22,000 respectively. Cell fractionation experiments indicate that the bcl-2 alpha gene product is located at the inner surface of the cell membrane, suggesting a possible role in mitogenic signal transduction. We report here that Bcl-2 alpha has GTP-binding activity and a protein sequence that suggests it belongs to the small molecular weight GTP-binding protein (G protein) family.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478890     DOI: 10.1038/342195a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  14 in total

1.  Distribution of polypeptides binding guanosine 5'-[gamma-[35S]thio]triphosphate and anti-(ras protein) antibodies in liver subcellular fractions. Evidence for endosome-specific components.

Authors:  N Ali; W H Evans
Journal:  Biochem J       Date:  1990-10-01       Impact factor: 3.857

2.  Complementation by BCL2 and C-HA-RAS oncogenes in malignant transformation of rat embryo fibroblasts.

Authors:  J C Reed; S Haldar; C M Croce; M P Cuddy
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

3.  Inactivation of Bcl-2 by phosphorylation.

Authors:  S Haldar; N Jena; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

4.  BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense.

Authors:  J C Reed; M Cuddy; S Haldar; C Croce; P Nowell; D Makover; K Bradley
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

Review 5.  Genomic profiles in B cell lymphoma.

Authors:  Masao Seto
Journal:  Int J Hematol       Date:  2010-08-27       Impact factor: 2.490

6.  Suppression of apoptosis in insect cells stably transfected with baculovirus p35: dominant interference by N-terminal sequences p35(1-76).

Authors:  J L Cartier; P A Hershberger; P D Friesen
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Overexpressed full-length human BCL2 extends the survival of baculovirus-infected Sf9 insect cells.

Authors:  E S Alnemri; N M Robertson; T F Fernandes; C M Croce; G Litwack
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

Review 8.  Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies.

Authors:  Alex R D Delbridge; Stephanie Grabow; Andreas Strasser; David L Vaux
Journal:  Nat Rev Cancer       Date:  2016-02       Impact factor: 60.716

9.  bcl-2 inhibits death of central neural cells induced by multiple agents.

Authors:  L T Zhong; T Sarafian; D J Kane; A C Charles; S P Mah; R H Edwards; D E Bredesen
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

10.  Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma.

Authors:  Elisa Oricchio; Natalya Katanayeva; Maria Christine Donaldson; Stephanie Sungalee; Joyce P Pasion; Wendy Béguelin; Elena Battistello; Viraj R Sanghvi; Man Jiang; Yanwen Jiang; Matt Teater; Anita Parmigiani; Andrei V Budanov; Fong Chun Chan; Sohrab P Shah; Robert Kridel; Ari M Melnick; Giovanni Ciriello; Hans-Guido Wendel
Journal:  Sci Transl Med       Date:  2017-06-28       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.